(Circulation. 1996;94:2793-2799.)
© 1996 American Heart Association, Inc.
Articles |
Double-Blind, Placebo-Controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart Failure
The PRECISE Trial
the College of Physicians and Surgeons, Columbia University, New York, NY (M.P., J.D.S.-B., M.K.); Boston (Mass) University School of Medicine (W.S.C.); University of Rochester (NY) School of Medicine (C.-S.L.); Good Samaritan Hospital, Baltimore, Md (D.A.G.); Nassau County Medical Center, East Meadow, NY (I.F.); Mount Sinai School of Medicine, New York, NY (M.L.K., N.E.K.); Henry Ford Hospital, Grosse Pointe, Mich (V.K.); Tufts University School of Medicine, Boston, Mass (J.E.U.); University of Maryland, Baltimore (S.S.G.); Georgetown University School of Medicine, Washington, DC (D.P.); Ohio State University School of Medicine, Columbus (R.J.C.); Overlook Hospital, Summit, NJ (J.J.G.); Albert Einstein School of Medicine, Bronx, NY (T.H.L.); and SmithKline Beecham Pharmaceuticals, King of Prussia, Pa (S.T.Y., M.A.L., N.H.S.).
Reprint requests to Dr Milton Packer, Division of Circulatory Physiology, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032.
Background Carvedilol has improved the symptomatic status of patients with moderate to severe heart failure in single-center studies, but its clinical effects have not been evaluated in large, multicenter trials.
Methods and Results We enrolled 278 patients with moderate to severe heart failure (6-minute walk distance, 150 to 450 m) and a left ventricular ejection fraction 
0.35 at 31 centers. After an open-label, run-in period, each patient was randomly assigned (double-blind) to either placebo (n=145) or carvedilol (n=133; target dose, 25 to 50 mg BID) for 6 months, while background therapy with digoxin, diuretics, and an ACE inhibitor remained constant. Compared with placebo, patients in the carvedilol group had a greater frequency of symptomatic improvement and lower risk of clinical deterioration, as evaluated by changes in the NYHA functional class (P=.014) or by a global assessment of progress judged either by the patient (P=.002) or by the physician (P<.001). In addition, treatment with carvedilol was associated with a significant increase in ejection fraction (P<.001) and a significant decrease in the combined risk of morbidity and mortality (P=.029). In contrast, carvedilol therapy had little effect on indirect measures of patient benefit, including changes in exercise tolerance or quality-of-life scores. The effects of the drug were similar in patients with ischemic heart disease or idiopathic dilated cardiomyopathy as the cause of heart failure.
Conclusions These findings indicate that, in addition to its favorable effects on survival, carvedilol produces important clinical benefits in patients with moderate to severe heart failure treated with digoxin, diuretics, and an ACE inhibitor. (Circulation. 1996;94:2793-2799.)
Key Words: heart failure • carvedilol • blockers, beta-adrenergic
This article has been cited by other articles:
 |
|
 |
|
  S. M. Zick, B. M. Vautaw, B. Gillespie, and K. D. Aaronson Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) Trial Eur J Heart Fail, October 1, 2009; 11(10): 990 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. McAlister, N. Wiebe, J. A. Ezekowitz, A. A. Leung, and P. W. Armstrong Meta-analysis: {beta}-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure Ann Intern Med, June 2, 2009; 150(11): 784 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J. Am. Coll. Cardiol., April 14, 2009; 53(15): e1 - e90. [Full Text] [PDF]
|
|
|
|
|
|
M. Jessup, W. T. Abraham, D. E. Casey, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. A. Konstam, D. M. Mancini, P. S. Rahko, M. A. Silver, et al. 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1343 - 1382. [Full Text] [PDF]
|
|
|
|
 |
|
 2009 WRITING GROUP TO REVIEW NEW EVIDENCE AND UPDA, M. Jessup, W. T. Abraham, D. E. Casey, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. A. Konstam, D. M. Mancini, P. S. Rahko, et al. 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation Circulation, April 14, 2009; 119(14): 1977 - 2016. [Full Text] [PDF]
|
|
|
|
|
|
2005 WRITING COMMITTEE MEMBERS, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation Circulation, April 14, 2009; 119(14): e391 - e479. [Full Text] [PDF]
|
|
|
|
|
|
J. T. Parissis, M. Nikolaou, D. Farmakis, I. A. Paraskevaidis, V. Bistola, K. Venetsanou, D. Katsaras, G. Filippatos, and D. T. Kremastinos Self-assessment of health status is associated with inflammatory activation and predicts long-term outcomes in chronic heart failure Eur J Heart Fail, February 1, 2009; 11(2): 163 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Albert Switching to Once-Daily Evidence-Based -Blockers in Patients With Systolic Heart Failure or Left Ventricular Dysfunction After Myocardial Infarction Crit. Care Nurse, December 1, 2007; 27(6): 62 - 72. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Chen, R. Chang, B. Umakanthan, L. N. Stoletniy, and J. T. Heywood Improvement of Cardiac Function Persists Long Term With Medical Therapy for Left Ventricular Systolic Dysfunction Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2007; 12(3): 220 - 226. [Abstract] [PDF]
|
|
|
|
 |
|
 L. A. Smith, M. Vennelle, R. S. Gardner, T. A. McDonagh, M. A. Denvir, N. J. Douglas, and D. E. Newby Auto-titrating continuous positive airway pressure therapy in patients with chronic heart failure and obstructive sleep apnoea: a randomized placebo-controlled trial Eur. Heart J., May 2, 2007; 28(10): 1221 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Oldenburg, B. Lamp, L. Faber, H. Teschler, D. Horstkotte, and V. Topfer Sleep-disordered breathing in patients with symptomatic heart failure A contemporary study of prevalence in and characteristics of 700 patients Eur J Heart Fail, March 1, 2007; 9(3): 251 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Abdulla, L. Kober, E. Christensen, and C. Torp-Pedersen Effect of beta-blocker therapy on functional status in patients with heart failure -- A meta-analysis Eur J Heart Fail, August 1, 2006; 8(5): 522 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Watanabe, H. Yaoita, K. Ogawa, M. Oikawa, K. Maehara, and Y. Maruyama Attenuated cardioprotection by ischemic preconditioning in coronary stenosed heart and its restoration by carvedilol Cardiovasc Res, August 1, 2006; 71(3): 537 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Passantino, R. Lagioia, F. Mastropasqua, and D. Scrutinio Short-Term Change in Distance Walked in 6 Min Is an Indicator of Outcome in Patients With Chronic Heart Failure in Clinical Practice J. Am. Coll. Cardiol., July 4, 2006; 48(1): 99 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Funck-Brentano Beta-blockade in CHF: from contraindication to indication Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C19 - C27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Shigeyama, Y. Yasumura, A. Sakamoto, Y. Ishida, T. Fukutomi, M. Itoh, K. Miyatake, and M. Kitakaze Increased gene expression of collagen Types I and III is inhibited by {beta}-receptor blockade in patients with dilated cardiomyopathy Eur. Heart J., December 2, 2005; 26(24): 2698 - 2705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Developed in Collaboration With the American Colle, Endorsed by the Heart Rhythm Society, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) J. Am. Coll. Cardiol., September 20, 2005; 46(6): 1116 - 1143. [Full Text] [PDF]
|
|
|
|
|
|
K. K.A. Witte, S. Thackray, N. P. Nikitin, J. G.F. Cleland, and A. L. Clark The effects of long-term {beta}-blockade on the ventilatory responses to exercise in chronic heart failure Eur J Heart Fail, June 1, 2005; 7(4): 612 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. O'Meara, E. Lewis, C. Granger, M. E. Dunlap, R. S. McKelvie, J. L. Probstfield, J. B. Young, E. L. Michelson, J. Ostergren, J. Carlsson, et al. Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme Eur J Heart Fail, June 1, 2005; 7(4): 650 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. G. Olsson, K. Swedberg, A. L. Clark, K. K. Witte, and J. G.F. Cleland Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review Eur. Heart J., April 2, 2005; 26(8): 778 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Refsgaard 'This is a walking test, not a talking test': the six minute walking test in congestive heart failure Eur. Heart J., April 2, 2005; 26(8): 749 - 750. [Full Text] [PDF]
|
|
|
|
|
|
H. Rickli, S. Steiner, K. Muller, and O. M. Hess Betablockers in heart failure: Carvedilol Safety Assessment (CASA 2-trial) Eur J Heart Fail, October 1, 2004; 6(6): 761 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Sirak, S. Jelic, and T. H. Le Jemtel Therapeutic update: Non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure J. Am. Coll. Cardiol., August 4, 2004; 44(3): 497 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ward The quality of life in heart failure Just talking about it will not make it better Eur J Heart Fail, August 1, 2004; 6(5): 535 - 537. [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. Ko, P. R. Hebert, C. S. Coffey, J. P. Curtis, J. M. Foody, A. Sedrakyan, and H. M. Krumholz Adverse Effects of {beta}-Blocker Therapy for Patients With Heart Failure: A Quantitative Overview of Randomized Trials Arch Intern Med, July 12, 2004; 164(13): 1389 - 1394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N G Bellenger, K Rajappan, S L Rahman, A Lahiri, U Raval, J Webster, G D Murray, A J S Coats, J G F Cleland, and D J Pennell Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study Heart, July 1, 2004; 90(7): 760 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A Movsesian Altered cAMP-mediated signalling and its role in the pathogenesis of dilated cardiomyopathy Cardiovasc Res, June 1, 2004; 62(3): 450 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Mansfield, N. C. Gollogly, D. M. Kaye, M. Richardson, P. Bergin, and M. T. Naughton Controlled Trial of Continuous Positive Airway Pressure in Obstructive Sleep Apnea and Heart Failure Am. J. Respir. Crit. Care Med., February 1, 2004; 169(3): 361 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Gaussin, J. E. Tomlinson, C. Depre, S. Engelhardt, C. L. Antos, G. Takagi, L. Hein, J. N. Topper, S. B. Liggett, E. N. Olson, et al. Common Genomic Response in Different Mouse Models of {beta}-Adrenergic-Induced Cardiomyopathy Circulation, December 9, 2003; 108(23): 2926 - 2933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zanolla and P. Zardini Selection of endpoints for heart failure clinical trials Eur J Heart Fail, December 1, 2003; 5(6): 717 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Higgins, J. D. Hummel, I. K. Niazi, M. C. Giudici, S. J. Worley, L. A. Saxon, J. P. Boehmer, M. B. Higginbotham, T. De Marco, E. Foster, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1454 - 1459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ferrari, S. Censi, F. Mastrorilli, and A. Boraso Prognostic benefits of heart rate reduction in cardiovascular disease Eur. Heart J. Suppl., September 1, 2003; 5(suppl_G): G10 - G14. [Abstract] [PDF]
|
|
|
|
|
|
A. Bouzamondo, J.-S. Hulot, P. Sanchez, and P. Lechat Beta-blocker benefit according to severity of heart failure Eur J Heart Fail, June 1, 2003; 5(3): 281 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Krum, E. B. Roecker, P. Mohacsi, J. L. Rouleau, M. Tendera, A. J. S. Coats, H. A. Katus, M. B. Fowler, M. Packer, and for the Carvedilol Prospective Randomized Cumulati Effects of Initiating Carvedilol in Patients With Severe Chronic Heart Failure: Results From the COPERNICUS Study JAMA, February 12, 2003; 289(6): 712 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Gitt, K. Wasserman, C. Kilkowski, T. Kleemann, A. Kilkowski, M. Bangert, S. Schneider, A. Schwarz, and J. Senges Exercise Anaerobic Threshold and Ventilatory Efficiency Identify Heart Failure Patients for High Risk of Early Death Circulation, December 10, 2002; 106(24): 3079 - 3084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Agostoni, M. Guazzi, M. Bussotti, S. De Vita, and P. Palermo Carvedilol Reduces the Inappropriate Increase of Ventilation During Exercise in Heart Failure Patients Chest, December 1, 2002; 122(6): 2062 - 2067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Baldasseroni, L. De Biase, C. Fresco, N. Marchionni, M. Marini, G. Masotti, G. Orsini, M. Porcu, F. Pozzar, M. Scherillo, et al. Cumulative effect of complete left bundle-branch block and chronic atrial fibrillation on 1-year mortality and hospitalization in patients with congestive heart failure. A report from the Italian network on congestive heart failure (in-CHF database) Eur. Heart J., November 1, 2002; 23(21): 1692 - 1698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. R. Heyen, E. R. Blasi, K. Nikula, R. Rocha, H. A. Daust, G. Frierdich, J. F. Van Vleet, P. De Ciechi, E. G. McMahon, and A. E. Rudolph Structural, functional, and molecular characterization of the SHHF model of heart failure Am J Physiol Heart Circ Physiol, November 1, 2002; 283(5): H1775 - H1784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Packer, M. B. Fowler, E. B. Roecker, A. J.S. Coats, H. A. Katus, H. Krum, P. Mohacsi, J. L. Rouleau, M. Tendera, C. Staiger, et al. Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Circulation, October 22, 2002; 106(17): 2194 - 2199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Pritchett and M. M. Redfield {beta}-Blockers: New Standard Therapy for Heart Failure Mayo Clin. Proc., August 1, 2002; 77(8): 839 - 846. [Abstract] [PDF]
|
|
|
|
 |
|
 W. T. Abraham, W. G. Fisher, A. L. Smith, D. B. Delurgio, A. R. Leon, E. Loh, D. Z. Kocovic, M. Packer, A. L. Clavell, D. L. Hayes, et al. Cardiac Resynchronization in Chronic Heart Failure N. Engl. J. Med., June 13, 2002; 346(24): 1845 - 1853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hulsmann, R. Berger, B. Sturm, A. Bojic, W. Woloszczuk, J. Bergler-Klein, and R. Pacher Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure Eur. Heart J., June 1, 2002; 23(11): 886 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Riegel, B. Carlson, Z. Kopp, B. LePetri, D. Glaser, and A. Unger Effect of a Standardized Nurse Case-Management Telephone Intervention on Resource Use in Patients With Chronic Heart Failure Arch Intern Med, March 25, 2002; 162(6): 705 - 712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kubo, E. R. Azevedo, G. E. Newton, J. D. Parker, and J. S. Floras Lack of evidence for peripheral alpha1- adrenoceptor blockade during long-term treatment of heart failure with carvedilol J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1463 - 1469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Gullestad, C. Manhenke, T. Aarsland, R. Skardal, H. Fagertun, J. Wikstrand, and J. Kjekshus Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure -- a substudy to the MERIT-HF trial Eur J Heart Fail, August 1, 2001; 3(4): 463 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. N. Singh CIBIS, MERIT-HF, and COPERNICUS Trial Outcomes: Do They Complete the Chapter on -Adrenergic Blockers as Antiarrhythmic and Antifibrillatory Drugs? Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2001; 6(2): 107 - 110. [PDF]
|
|
|
|
|
|
C. Berry, D. R. Murdoch, and J. J.V. McMurray Economics of chronic heart failure Eur J Heart Fail, June 1, 2001; 3(3): 283 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.F. Forissier, P. Vernochet, P. Bertrand, B. Charbonnier, and C. Monpere Influence of carvedilol on the benefits of physical training in patients with moderate chronic heart failure Eur J Heart Fail, June 1, 2001; 3(3): 335 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Shibata, M. D. Flather, and D. Wang Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure Eur J Heart Fail, June 1, 2001; 3(3): 351 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Wallhaus, M. Taylor, T. R. DeGrado, D. C. Russell, P. Stanko, R. J. Nickles, and C. K. Stone Myocardial Free Fatty Acid and Glucose Use After Carvedilol Treatment in Patients With Congestive Heart Failure Circulation, May 22, 2001; 103(20): 2441 - 2446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. W. Yancy, M. B. Fowler, W. S. Colucci, E. M. Gilbert, M. R. Bristow, J. N. Cohn, M. A. Lukas, S. T. Young, M. Packer, and the U.S. Carvedilol Heart Failure Study Group Race and the Response to Adrenergic Blockade with Carvedilol in Patients with Chronic Heart Failure N. Engl. J. Med., May 3, 2001; 344(18): 1358 - 1365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Kaye, L. Johnston, G. Vaddadi, H. Brunner-LaRocca, G. L. Jennings, and M. D. Esler Mechanisms of Carvedilol Action in Human Congestive Heart Failure Hypertension, May 1, 2001; 37(5): 1216 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Brophy, L. Joseph, and J. L. Rouleau {beta}-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis Ann Intern Med, April 3, 2001; 134(7): 550 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. N. Singh and J. S. M. Sarma Mechanisms of Action of Antiarrhythmic Drugs Relative to the Origin and Perpetuation of Cardiac Arrhythmias Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2001; 6(1): 69 - 87. [PDF]
|
|
|
|
|
|
T. M. Ramahi, M. D. Longo, A. R. Cadariu, K. Rohlfs, S. A. Carolan, K. M. Engle, H. Samady, and F. J. T. Wackers Left ventricular inotropic reserve and right ventricular function predict increase of left ventricular ejection fraction after beta-blocker therapy in nonischemic cardiomyopathy J. Am. Coll. Cardiol., March 1, 2001; 37(3): 818 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gomberg-Maitland, D. A. Baran, and V. Fuster Treatment of Congestive Heart Failure: Guidelines for the Primary Care Physician and the Heart Failure Specialist Arch Intern Med, February 12, 2001; 161(3): 342 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Baartscheer Adenovirus gene transfer of SERCA in heart failure. A promising therapeutic approach ? Cardiovasc Res, February 1, 2001; 49(2): 249 - 252. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Geraci and A. A. Knowlton Spironolactone for Heart Failure : Spiraling Out of Control Chest, December 1, 2000; 118(6): 1522 - 1523. [Full Text] [PDF]
|
|
|
|
|
|
K. L. Grady, K. Dracup, G. Kennedy, D. K. Moser, M. Piano, L. W. Stevenson, and J. B. Young Team Management of Patients With Heart Failure : A Statement for Healthcare Professionals From the Cardiovascular Nursing Council of the American Heart Association Circulation, November 7, 2000; 102(19): 2443 - 2456. [Full Text] [PDF]
|
|
|
|
|
|
H. N. Sabbah, V. G. Sharov, R. C. Gupta, A. Todor, V. Singh, and S. Goldstein Chronic therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1698 - 1705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Bristow What Type of {beta}-Blocker Should Be Used to Treat Chronic Heart Failure? Circulation, August 1, 2000; 102(5): 484 - 486. [Full Text] [PDF]
|
|
|
|
|
|
W. T. Abraham {beta}-Blockers: The New Standard of Therapy for Mild Heart Failure Arch Intern Med, May 8, 2000; 160(9): 1237 - 1247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Green, C. B. Porter, D. R. Bresnahan, and J. A. Spertus Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure J. Am. Coll. Cardiol., April 1, 2000; 35(5): 1245 - 1255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Vatner, D. E. Vatner, and C. J. Homcy {beta}-Adrenergic Receptor Signaling: An Acute Compensatory Adjustment--Inappropriate for the Chronic Stress of Heart Failure? : Insights from Gs{alpha} Overexpression and Other Genetically Engineered Animal Models Circ. Res., March 17, 2000; 86(5): 502 - 506. [Full Text] [PDF]
|
|
|
|
|
|
S. Bonet, A. Agusti, J. M. Arnau, X. Vidal, E. Diogene, E. Galve, and J.-R. Laporte {beta}-Adrenergic Blocking Agents in Heart Failure: Benefits of Vasodilating and Nonvasodilating Agents According to Patients' Characteristics: A Meta-analysis of Clinical Trials Arch Intern Med, March 13, 2000; 160(5): 621 - 627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hjalmarson, S. Goldstein, B. Fagerberg, H. Wedel, F. Waagstein, J. Kjekshus, J. Wikstrand, D. El Allaf, J. Vitovec, J. Aldershvile, et al. Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients With Heart Failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) JAMA, March 8, 2000; 283(10): 1295 - 1302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. St. John Sutton Aortic stiffness: a predictor of acute coronary events? Eur. Heart J., March 1, 2000; 21(5): 342 - 344. [PDF]
|
|
|
|
|
|
J. N. Cohn, R. Ferrari, N. Sharpe, and on Behalf of an International Forum on Cardiac Rem Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling J. Am. Coll. Cardiol., March 1, 2000; 35(3): 569 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Bristow {beta}-Adrenergic Receptor Blockade in Chronic Heart Failure Circulation, February 8, 2000; 101(5): 558 - 569. [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Walker, F. A. Crawford Jr, and F. G. Spinale MYOCYTE CONTRACTILE DYSFUNCTION WITH HYPERTROPHY AND FAILURE: RELEVANCE TO CARDIAC SURGERY J. Thorac. Cardiovasc. Surg., February 1, 2000; 119(2): 388 - 400. [Full Text] [PDF]
|
|
|
|
|
|
G. Z. Feuerstein and P. R. Young Apoptosis in cardiac diseases: stress- and mitogen-activated signaling pathways Cardiovasc Res, February 1, 2000; 45(3): 560 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. N. Singh Initial Antiarrhythmic Drug Therapy During Resuscitation from Sudden Cardiac Death: A Time for a Fundamental Change in Strategy? Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(1): 3 - 9. [PDF]
|
|
|
|
|
|
S. Doshi and B. N. Singh Reducing Perioperative Cardiac Risk in Noncardiac Surgery: A Time to Delineate Simpler Strategies? Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(2): 69 - 75. [PDF]
|
|
|
|
|
|
J. E. Sanderson, S. K. W. Chan, G. Yip, L. Y. C. Yeung, K. W. Chan, K. Raymond, and K. S. Woo Beta-blockade in heart failure: A comparison of carvedilol with metoprolol J. Am. Coll. Cardiol., November 1, 1999; 34(5): 1522 - 1528. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.H. Davies and Y. Bashir Beta-blockers for heart failure-time to think the unthinkable? QJM, November 1, 1999; 92(11): 673 - 678. [Full Text] [PDF]
|
|
|
|
|
|
H Kitaoka, J Takata, T Yabe, N Hitomi, T Furuno, and Y L Doi Low dose dobutamine stress echocardiography predicts the improvement of left ventricular systolic function in dilated cardiomyopathy Heart, May 1, 1999; 81(5): 523 - 527. [Abstract] [Full Text]
|
|
|
|
|
|
D. L. Dries, D. V. Exner, B. J. Gersh, H. A. Cooper, P. E. Carson, and M. J. Domanski Racial Differences in the Outcome of Left Ventricular Dysfunction N. Engl. J. Med., February 25, 1999; 340(8): 609 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Richards, R. Doughty, M. G. Nicholls, S. Macmahon, H. Ikram, N. Sharpe, E. A. Espiner, C. Frampton, and T. G. Yandle Neurohumoral Prediction of Benefit From Carvedilol in Ischemic Left Ventricular Dysfunction Circulation, February 16, 1999; 99(6): 786 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. P. Sharma, J. S.M. Sarma, and B. N. Singh Effects of Sotalol on the Circadian Rhythmicity of Heart Rate and QT Intervals With a Noninvasive Index of Reverse-Use Dependency Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1999; 4(1): 15 - 21. [Abstract] [PDF]
|
|
|
|
|
|
W. H. Frishman Carvedilol N. Engl. J. Med., December 10, 1998; 339(24): 1759 - 1765. [Full Text] [PDF]
|
|
|
|
|
|
H. Watanabe, M. Kakihana, S. Ohtsuka, and Y. Sugishita Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure J. Am. Coll. Cardiol., November 1, 1998; 32(5): 1194 - 1200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Watanabe, M. Kakihana, S. Ohtsuka, and Y. Sugishita Preventive effects of carvedilol on nitrate tolerance--a randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol J. Am. Coll. Cardiol., November 1, 1998; 32(5): 1201 - 1206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Lechat, M. Packer, S. Chalon, M. Cucherat, T. Arab, and J.-P. Boissel Clinical Effects of ß-Adrenergic Blockade in Chronic Heart Failure : A Meta-Analysis of Double-Blind, Placebo-Controlled, Randomized Trials Circulation, September 22, 1998; 98(12): 1184 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. A. Umans, J. H. Cornel, C. Hic, J. Soto, C. Avendano, F. G. Vilchez, M. Bohm, S. Zoneraich, S. Yusuf, R. Gorlin, et al. Digoxin in Patients with Heart Failure N. Engl. J. Med., July 10, 1997; 337(2): 129 - 131. [Full Text]
|
|
|
|
|
|
K. Ogunyankin and B. N. Singh Reflections on Recent Clinical Trials in Patients With Heart Failure and Those With Reduced Ventricular Function Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(3): 147 - 152. [PDF]
|
|
|
|
 |
|
 MORE STUDIES SUPPORT CARVEDILOL FOR HEART FAILURE Journal Watch (General), December 31, 1996; 1996(1231): 1 - 1. [Full Text]
|
|
|
|
|
|
K. Chatterjee Heart Failure Therapy in Evolution Circulation, December 1, 1996; 94(11): 2689 - 2693. [Full Text]
|
|